Recent scrutiny has emerged regarding the New England Journal of Medicine (NEJM) for its failure to publish important data from a Pfizer flu vaccine trial that involved older adults. The omission of results for individuals aged 65 and older has raised significant questions about the integrity of the publication process and the implications for public health.
1. Missing Data Announcement:
• Pfizer's mRNA flu vaccine showed little benefit for adults aged 18-64, and the adverse effects were more significant than reported.
• Data from the older adult cohort (65+) was not included in the NEJM publication but was found on ClinicalTrials.gov, beyond public view.
2. Criticism from Experts:
• MIT professor Retsef Levi criticized the NEJM for not publishing outcomes from older participants, noting it was unacceptable given their vulnerability.
• Levi stated the omission seemed deliberate as the results were not favorable for the mRNA vaccine compared to traditional flu shots, stating it raises concerns over the journal's scientific integrity.
3. NEJM's Response:
• Levi described the lack of inclusion of this data in NEJM as a serious oversight, undermining the transparency expected in medical journals.
• He pointed out that the journal editor-in-chief, Dr. Eric Rubin, must provide an explanation for this gap, suggesting a fail in the review process.
4. Concerns Over Rubin's Role:
• Dr. Rubin also serves on the FDA committee that could review Pfizer's vaccine, leading to concerns about conflicts of interest and impartiality in evaluating the vaccine.
• During previous health discussions, Rubin had minimized safety concerns related to vaccines, demonstrating a questionable approach to public health communication.
5. Regulatory Capture and Selective Reporting:
• The situation has been characterized as regulatory capture, where a manufacturer’s trial results favored by publications leads to a lack of transparency.
• Levi emphasized the importance of complete and truthful reporting in scientific conduct, arguing that selective reporting has eroded public trust in health science.
The NEJM's failure to report on critical data regarding Pfizer's flu vaccine for seniors represents a troubling case of selective publication practices that could misinform healthcare decisions. The events surrounding this issue not only question the integrity of the findings but also the actions of those in positions of authority within the FDA. Moving forward, calls for transparency from both NEJM and regulatory bodies are imperative to restore public confidence in health sciences and ensure accountability for maintaining ethical standards in medical research. There are expectations for NEJM to correct the omission and adhere to ethical reporting standards, which are crucial for public health discourse.
No comments:
Post a Comment